Inderm

Erythromycin, the active ingredient in Inderm, is a macrolide antibiotic presented as a topical formulation for topical use. It treats acne vulgaris and superficial skin infections by targeting susceptible bacteria on the skin surface. GNH USA supplies Inderm as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Erythromycin is a macrolide antibiotic used for bacterial skin conditions that respond to topical therapy.

Acne vulgaris: reduces inflammatory lesions and bacterial colonisation on the skin. Superficial skin infections: eradicates susceptible organisms causing impetigo, erysipelas or cellulitis of limited depth. Impetigo: clears Staphylococcus aureus or Streptococcus pyogenes infection and promotes healing of crusted lesions.

Topical erythromycin may cause local skin reactions and, rarely, systemic hypersensitivity.

Common Side Effects: - Skin irritation or burning sensation at the application site. - Itching or pruritus. - Redness (erythema) of the treated area. - Dryness or peeling of the skin. - Mild contact dermatitis. - Stinging sensation.

Serious or Rare Side Effects: - Severe allergic reaction (anaphylaxis) with swelling, hives, or difficulty breathing. - Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Drug‑induced liver injury (hepatitis) reported with extensive absorption. - Serum sickness‑like reaction. - Persistent ulceration or necrosis of the skin.

Before using Inderm, consider the following safety measures. - Allergy assessment: avoid if the patient has known hypersensitivity to macrolides. - Skin integrity: do not apply on open wounds or severely damaged skin. - Monitor for systemic effects: watch for signs of gastrointestinal upset or liver dysfunction. - Concomitant topical antibiotics: limit combined use to reduce resistance risk. - Eye protection: keep product away from eyes and mucous membranes. - Store at below 25°C: keep in the original container, protect from moisture and direct sunlight.

Erythromycin can interact with other medicines, affecting safety or efficacy.

Major Interactions (Avoid): - Co‑administration with other macrolide antibiotics: may increase systemic exposure and toxicity. - Drugs that prolong the QT interval (e.g., certain antiarrhythmics): risk of cardiac arrhythmias. - Concurrent use with topical corticosteroids: may mask signs of infection.

Moderate Interactions (Monitor Closely): - CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may raise erythromycin levels. - Antacids containing aluminum or magnesium: could reduce local absorption. - Warfarin: monitor INR as erythromycin may enhance anticoagulant effect.